OmniActive’s fourth facility successfully passes rigorous FDA audit
Supa facility in India passes CFR 110 cGMP inspection
OmniActive Health Technologies’ Supa facility in India is the fourth to successfully go through the FDA CFR 110 cGMP audit, joining our facilities in Oros, Pune and Talwar.
'OmniActive consistently strives to meet the highest quality and regulatory controls by continuously optimising our operations and facilities,' stated Chaitanya Desai, COO. 'Our efforts in meeting and exceeding the world’s strictest standards serve as the foundation of our achievements, as recognised by the FDA.'
OmniActive ensures that all personnel are fully trained in several aspects of operational excellence and quality control standards, and its facilities are both cGMP- and ISO9005:22000-certified. In addition, as a responsible supplier, OmniActive’s ingredients are produced through effective, efficient and sustainable operations.
'We take great pride in our efforts, and being recognised for doing so under rigorous analysis by the US FDA further solidifies our dedication to deliver the industry with premium, innovative ingredients,' said Lynda Doyle, Vice President, Global Marketing, OmniActive.
